Immunization of primates with a newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus

Joshua M. DiNapoli, Lijuan Yang, Amorsolo Suguitan, Subbiah Elankumaran, David W. Dorward, Brian R. Murphy, Siba K. Samal, Peter L. Collins, Alexander Bukreyev

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The ongoing outbreak of highly pathogenic avian influenza virus (HPAIV) in birds, the incidence of transmission to humans with a resulting high mortality rate, and the possibility of a human pandemic warrant the development of effective human vaccines against HPAIV. We developed an experimental live-attenuated vaccine for direct inoculation of the respiratory tract based on recombinant avian Newcastle disease virus (NDV) expressing the hemagglutinin (HA) glycoprotein of H5N1 HPAIV (NDV-HA). Expression of the HPAIV HA gene slightly reduced NDV virulence, as evidenced by the increased mean embryo death time and reduced replication in chickens. NDV-HA was administered to African green monkeys in two doses of 2 × 107 infectious units each with a 28-day interval to evaluate the systemic and local antibody responses specific to H5N1 HPAIV. The virus was shed only at low titers from the monkeys, indicative of safety. Two doses of NDV-HA induced a high titer of H5N1 HPAIV-neutralizing serum antibodies in all of the immunized monkeys. Moreover, a substantial mucosal immunoglobulin A response was induced in the respiratory tract after one and two doses. The titers of neutralizing antibodies achieved in this study suggest that the vaccine would be likely to prevent mortality and reduce morbidity caused by the H5N1 HPAIV. In addition, induction of a local immune response in the respiratory tract is an important advantage that is likely to reduce or prevent transmission of the virus during an outbreak or a pandemic. This vaccine is a candidate for clinical evaluation in humans.

Original languageEnglish (US)
Pages (from-to)11560-11568
Number of pages9
JournalJournal of Virology
Volume81
Issue number21
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Newcastle disease virus
Influenza in Birds
Neutralizing Antibodies
Orthomyxoviridae
neutralizing antibodies
Influenza A virus
respiratory system
Respiratory System
Primates
Immunization
immunization
Vaccines
hemagglutinins
vaccines
Hemagglutinins
Serum
live vaccines
pandemic
Pandemics
monkeys

ASJC Scopus subject areas

  • Immunology

Cite this

Immunization of primates with a newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. / DiNapoli, Joshua M.; Yang, Lijuan; Suguitan, Amorsolo; Elankumaran, Subbiah; Dorward, David W.; Murphy, Brian R.; Samal, Siba K.; Collins, Peter L.; Bukreyev, Alexander.

In: Journal of Virology, Vol. 81, No. 21, 11.2007, p. 11560-11568.

Research output: Contribution to journalArticle

DiNapoli, Joshua M. ; Yang, Lijuan ; Suguitan, Amorsolo ; Elankumaran, Subbiah ; Dorward, David W. ; Murphy, Brian R. ; Samal, Siba K. ; Collins, Peter L. ; Bukreyev, Alexander. / Immunization of primates with a newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. In: Journal of Virology. 2007 ; Vol. 81, No. 21. pp. 11560-11568.
@article{fb7b0586accd42e5a8177721e962e435,
title = "Immunization of primates with a newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus",
abstract = "The ongoing outbreak of highly pathogenic avian influenza virus (HPAIV) in birds, the incidence of transmission to humans with a resulting high mortality rate, and the possibility of a human pandemic warrant the development of effective human vaccines against HPAIV. We developed an experimental live-attenuated vaccine for direct inoculation of the respiratory tract based on recombinant avian Newcastle disease virus (NDV) expressing the hemagglutinin (HA) glycoprotein of H5N1 HPAIV (NDV-HA). Expression of the HPAIV HA gene slightly reduced NDV virulence, as evidenced by the increased mean embryo death time and reduced replication in chickens. NDV-HA was administered to African green monkeys in two doses of 2 × 107 infectious units each with a 28-day interval to evaluate the systemic and local antibody responses specific to H5N1 HPAIV. The virus was shed only at low titers from the monkeys, indicative of safety. Two doses of NDV-HA induced a high titer of H5N1 HPAIV-neutralizing serum antibodies in all of the immunized monkeys. Moreover, a substantial mucosal immunoglobulin A response was induced in the respiratory tract after one and two doses. The titers of neutralizing antibodies achieved in this study suggest that the vaccine would be likely to prevent mortality and reduce morbidity caused by the H5N1 HPAIV. In addition, induction of a local immune response in the respiratory tract is an important advantage that is likely to reduce or prevent transmission of the virus during an outbreak or a pandemic. This vaccine is a candidate for clinical evaluation in humans.",
author = "DiNapoli, {Joshua M.} and Lijuan Yang and Amorsolo Suguitan and Subbiah Elankumaran and Dorward, {David W.} and Murphy, {Brian R.} and Samal, {Siba K.} and Collins, {Peter L.} and Alexander Bukreyev",
year = "2007",
month = "11",
doi = "10.1128/JVI.00713-07",
language = "English (US)",
volume = "81",
pages = "11560--11568",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "21",

}

TY - JOUR

T1 - Immunization of primates with a newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus

AU - DiNapoli, Joshua M.

AU - Yang, Lijuan

AU - Suguitan, Amorsolo

AU - Elankumaran, Subbiah

AU - Dorward, David W.

AU - Murphy, Brian R.

AU - Samal, Siba K.

AU - Collins, Peter L.

AU - Bukreyev, Alexander

PY - 2007/11

Y1 - 2007/11

N2 - The ongoing outbreak of highly pathogenic avian influenza virus (HPAIV) in birds, the incidence of transmission to humans with a resulting high mortality rate, and the possibility of a human pandemic warrant the development of effective human vaccines against HPAIV. We developed an experimental live-attenuated vaccine for direct inoculation of the respiratory tract based on recombinant avian Newcastle disease virus (NDV) expressing the hemagglutinin (HA) glycoprotein of H5N1 HPAIV (NDV-HA). Expression of the HPAIV HA gene slightly reduced NDV virulence, as evidenced by the increased mean embryo death time and reduced replication in chickens. NDV-HA was administered to African green monkeys in two doses of 2 × 107 infectious units each with a 28-day interval to evaluate the systemic and local antibody responses specific to H5N1 HPAIV. The virus was shed only at low titers from the monkeys, indicative of safety. Two doses of NDV-HA induced a high titer of H5N1 HPAIV-neutralizing serum antibodies in all of the immunized monkeys. Moreover, a substantial mucosal immunoglobulin A response was induced in the respiratory tract after one and two doses. The titers of neutralizing antibodies achieved in this study suggest that the vaccine would be likely to prevent mortality and reduce morbidity caused by the H5N1 HPAIV. In addition, induction of a local immune response in the respiratory tract is an important advantage that is likely to reduce or prevent transmission of the virus during an outbreak or a pandemic. This vaccine is a candidate for clinical evaluation in humans.

AB - The ongoing outbreak of highly pathogenic avian influenza virus (HPAIV) in birds, the incidence of transmission to humans with a resulting high mortality rate, and the possibility of a human pandemic warrant the development of effective human vaccines against HPAIV. We developed an experimental live-attenuated vaccine for direct inoculation of the respiratory tract based on recombinant avian Newcastle disease virus (NDV) expressing the hemagglutinin (HA) glycoprotein of H5N1 HPAIV (NDV-HA). Expression of the HPAIV HA gene slightly reduced NDV virulence, as evidenced by the increased mean embryo death time and reduced replication in chickens. NDV-HA was administered to African green monkeys in two doses of 2 × 107 infectious units each with a 28-day interval to evaluate the systemic and local antibody responses specific to H5N1 HPAIV. The virus was shed only at low titers from the monkeys, indicative of safety. Two doses of NDV-HA induced a high titer of H5N1 HPAIV-neutralizing serum antibodies in all of the immunized monkeys. Moreover, a substantial mucosal immunoglobulin A response was induced in the respiratory tract after one and two doses. The titers of neutralizing antibodies achieved in this study suggest that the vaccine would be likely to prevent mortality and reduce morbidity caused by the H5N1 HPAIV. In addition, induction of a local immune response in the respiratory tract is an important advantage that is likely to reduce or prevent transmission of the virus during an outbreak or a pandemic. This vaccine is a candidate for clinical evaluation in humans.

UR - http://www.scopus.com/inward/record.url?scp=35448972595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448972595&partnerID=8YFLogxK

U2 - 10.1128/JVI.00713-07

DO - 10.1128/JVI.00713-07

M3 - Article

VL - 81

SP - 11560

EP - 11568

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 21

ER -